- In October 2024, Roquette unveiled PEARLITOL® 200 INH, a mannitol-based excipient specifically engineered for dry powder inhalers (DPIs). Developed in synergy with Qualicaps’ inhalation capsules, this innovation reflects Roquette’s commitment to enhancing pulmonary drug delivery. PEARLITOL 200 INH features optimized particle size distribution, non-hygroscopic properties, and low reducing sugar content, making it highly compatible with moisture-sensitive active pharmaceutical ingredients. The collaboration leverages Roquette’s excipient expertise and Qualicaps’ capsule technology to deliver efficient, reliable, and patient-friendly inhalation therapies
- In October 2023, JRS Pharma, a global leader in microcrystalline cellulose (MCC) and excipient technologies, announced the acquisition of a smaller competitor specializing in cellulose-based excipients. This strategic move expands JRS Pharma’s product portfolio and reinforces its position in both the pharmaceutical and food industries. By integrating the acquired company’s expertise and product lines, JRS aims to enhance its capabilities in formulation support, supply chain resilience, and customer-specific solutions across global markets
- In September 2023, Sigachi Industries Ltd., a global leader in microcrystalline cellulose (MCC) manufacturing, introduced a new line of MCC products specifically formulated for the food industry, with a strong emphasis on clean-label applications. These products cater to the rising consumer demand for transparency, natural ingredients, and sustainable sourcing in food formulations. By offering MCC that aligns with clean-label standards—free from synthetic additives and compliant with global food safety regulations—Sigachi reinforces its commitment to innovative, health-conscious food solutions
- In August 2023, FMC Corporation entered a strategic partnership with a leading biotechnology firm to explore the sustainable production of microcrystalline cellulose (MCC) from renewable resources. This collaboration reflects the chemical industry’s accelerating shift toward eco-friendly manufacturing, especially in sectors such as food and pharmaceuticals, where MCC is widely used as a binder, stabilizer, and texturizer. By leveraging biotechnology and renewable feedstocks, the initiative aims to reduce environmental impact while maintaining high product performance and regulatory compliance
- In February 2023, Asahi Kasei completed construction of its second Ceolus™ microcrystalline cellulose (MCC) plant at the Mizushima Works in Kurashiki, Okayama, Japan. This expansion was driven by the surging global demand for MCC, particularly for use as a tablet binder in pharmaceutical and nutraceutical formulations. The new facility enhances production capacity and supply stability, especially for high-performance grades such as Ceolus™ KG and Ceolus™ UF, which support challenging formulations and enable high-speed tableting with fewer impurities
